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Traumatic brain injury (TBI) and Alzheimer’s disease (AD) are diseases during which the
fine-tuned autoregulation of the brain is lost. Despite the stark contrast in their causal
mechanisms, both TBI and AD are conditions which elicit a neuroinflammatory response
that is coupled with physical, cognitive, and affective symptoms. One commonly
reported symptom in both TBI and AD patients is disturbed sleep. Sleep is regulated by
circadian and homeostatic processes such that pathological inflammation may disrupt
the chemical signaling required to maintain a healthy sleep profile. In this way, immune
system activation can influence sleep physiology. Conversely, sleep disturbances can
exacerbate symptoms or increase the risk of inflammatory/neurodegenerative diseases.
Both TBI and AD are worsened by a chronic pro-inflammatory microenvironment
which exacerbates symptoms and worsens clinical outcome. Herein, a positive
feedback loop of chronic inflammation and sleep disturbances is initiated. In this
review, the bidirectional relationship between sleep disturbances and inflammation is
discussed, where chronic inflammation associated with TBI and AD can lead to sleep
disturbances and exacerbated neuropathology. The role of microglia and cytokines in
sleep disturbances associated with these diseases is highlighted. The proposed sleep
and inflammation-mediated link between TBI and AD presents an opportunity for a
multifaceted approach to clinical intervention.
Keywords: sleep, inflammation, traumatic brain injury, concussion, Alzheimer’s disease, cytokines, microglia,
neurodegeneration
INTRODUCTION
In diseased states affecting the central nervous system (CNS), the fine-tuned autoregulation of
the brain is lost, which contributes to the affective and cognitive symptoms seen in psychiatric,
neurological, and mental health disorders (Charrier et al., 2017). Alzheimer’s disease (AD) is a
neurodegenerative disorder that impacts approximately 1 in 10 people over the age of 65 and 1 in 3
people over the age of 85 (Newcombe et al., 2018). AD has a long prodromal phase and progresses
slowly, across a span of typically around 10 years. In contrast, traumatic brain injury (TBI) is a rapid
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onset condition which can occur at any age due to impact to
the head. It has been suggested that TBI heightens the risk of
subsequent development of AD (Mendez, 2017). Despite the
stark contrast in their causal mechanisms, both AD and TBI
are conditions which elicit a neuroinflammatory response that
is coupled with physical, cognitive, and affective symptoms.
A commonly reported symptom in both AD and TBI is sleep
disturbance (Vitiello and Borson, 2001; Castriotta et al., 2007;
Viola-Saltzman and Watson, 2012; Sandsmark et al., 2017).
Sleep is regulated by circadian and homeostatic processes,
such that pathological inflammation may disrupt the chemical
signaling required to maintain a healthy sleep profile. In this
way, immune system activation can influence sleep physiology.
Conversely, sleep disturbances can exacerbate symptoms or
increase the risk of inflammatory/neurodegenerative diseases.
The coupling between sleep and inflammation may indicate
clinical disease status or outcome of disease processes (Wiseman-
Hakes et al., 2013; Rao et al., 2014). The self-perpetuating cycle
of sleep disturbance and neuroinflammation seen in TBI and AD
encourage a comparison of these seemingly disparate conditions
to gain greater insight into the shared mechanisms of progressive
symptomology. This review will discuss the possibility of a sleep-
and inflammation-fueled progression from TBI to AD.
TBI is characterized by a primary insult, initiated by
mechanical forces applied to the head or brain. Immediately,
sequential pathophysiological processes are initiated, which often
result in a chronic inflammatory microenvironment. Microglia
and resident mononuclear phagocytes throughout the CNS are
activated as part of this secondary injury process in an attempt
to preserve homeostasis and repair injured tissue. TBI-induced
inflammation is communicated by pro- and anti-inflammatory
cytokines, which are below detectable levels in healthy tissue but
rapidly increase upon impact (Wang and Shuaib, 2002; Lucas
et al., 2006). Cytokines are powerful chemical communicators,
essential for maintaining homeostasis throughout the body.
However, unregulated release of pro-inflammatory cytokines
following an injury can cause pathological functions that lead
to detrimental inflammation and progressive tissue damage
(Kumar and Loane, 2012; Morganti-Kossmann et al., 2018).
Cytokines released by microglia act as sleep regulatory substances
(SRSs) and help to maintain healthy sleep (Krueger and Majde,
1995). Therefore, TBI-induced elevation of cytokines can lead
to sleep disturbances. Hereon, cytokine-mediated inflammatory
cascades and sleep enter a self-perpetuating positive-feedback
loop, containing many of the components seen in the molecular
circuitry of sleep disturbances in AD (as shown in Figure 1).
AD, much like TBI, is associated with a range of cognitive and
non-cognitive symptoms that include memory loss, disturbed
sleep, speech difficulties, depression, and loss of executive
function (Burns and Iliffe, 2009). Preceding cognitive decline, the
aggregation of amyloid-β plaques and tau neurofibrillary tangles
occurs in the brain, both of which are required for a retrospective
AD diagnosis after death (Murphy and LeVine, 2010). While a
minority of cases are genetically linked, most do not have an
identified cause which makes AD hard to predict, characterize,
diagnose, and treat (Newcombe et al., 2018). Preexisting diseases
and lifestyle factors can also contribute to an increased risk of
FIGURE 1 | TBI to AD, an inter-disease trajectory. TBI disrupts the blood brain
barrier (BBB) upon insult which results in an infiltration of peripheral
pro-inflammatory cytokines and any soluble pools of amyloid-β (Aβ) and Tau.
Together, these can precipitate AD. As some pro-inflammatory cytokines have
dual (opposing) roles as sleep regulatory substances, their increase can also
lead to sleep disturbances, a characteristic that commonly precedes the
cognitive decline in AD. Pro-inflammatory cytokines upregulate the activation
of microglia, which act as a positive feedback mechanism, resulting in
increased pro-inflammatory cytokine production and an increased breach of
the BBB. Unregulated cytokine release also sustains microglial activation and
priming which results in a chronic pro-inflammatory microenvironment. This
includes astrocytosis, hypoxia, reactive oxygen species (ROS), elevated
cytokine levels, and microglial activation. The movement of amyloid-β (Aβ) and
Tau through the breach in the BBB could potentially seed protein
oligomerization and aggregation, thereby acting as possible drivers of central
plaque and tangle pathology. Such aggregates in the brain further contribute
to microglial activation, the pro-inflammatory microenvironment, and neuronal
apoptosis. Together, these contribute to cognitive dysfunction and brain
atrophy, the key pathological features of AD. Both brain atrophy and neuronal
death help to sustain the pro-inflammatory microenvironment creating a
self-perpetuating feedback loop.
AD (Faden and Loane, 2015). These include TBI, a common
injury which increases the frequency and onset of AD and
other related dementias (McKee et al., 2009; Gavett et al., 2010;
Gavett et al., 2011; Baugh et al., 2012). Similar to TBI, AD
has a neuroinflammatory component that is orchestrated by
pro-inflammatory cytokines and activated microglia. Although
inflammation has a beneficial role in clearing cellular debris
and apoptotic cells associated with AD, chronic inflammation
can be damaging due to pro-inflammatory intermediates that
compromise future clearance mechanisms, synaptic pruning,
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and neuronal survival (Solito and Sastre, 2012; Sarlus and
Heneka, 2017). Moreover, the cytokine storm associated with
chronic inflammation can disrupt sleep-wake cycles, a symptom
frequently observed in AD patients. Sleep disturbances cause
further cytokine release and microglial activation, hence a
positive feedback loop of chronic inflammation and sleep
disturbance is initiated (as shown in Figure 1).
In this review, we discuss the bidirectional relationship
between sleep disturbance and inflammation, such that chronic
inflammation associated with TBI and AD can lead to sleep
disturbances that exacerbate neuropathology. We also highlight
the role of microglia and cytokines in sleep disturbances
associated with these diseases.
THE ROLE OF SLEEP ON HOMEOSTASIS
While sleep is an evolutionarily conserved phenomenon that
is essential for survival (Banks and Dinges, 2007), its function
is not fully understood. The roles of sleep in the elimination
of waste, restoration of depleted energy sources (Oswald, 1980;
Dworak et al., 2010), and energy conservation (Walker and
Berger, 1980; Xie et al., 2013) have long been characterized.
Sleep plays a physiological role in the cardiovascular, metabolic,
thermoregulatory, respiratory, and sexual systems, as well as
having a major role in regulating brain health and function. More
recent hypotheses suggest a cellular need for sleep in regulating
brain plasticity (Puentes-Mestril and Aton, 2017), learning, and
memory (Tononi and Cirelli, 2003; Huber et al., 2004; Tononi
and Cirelli, 2014; Miyamoto et al., 2017; Raven et al., 2018).
Indeed, in the absence of sleep, there is significant detriment to
cognitive function (Krueger et al., 1999).
The sleep-wake cycle is essential in regulating many of the
body’s fine-tuned homeostatic processes, even on a molecular
level (Cirelli and Tononi, 2008). A study, using two-photon
imaging of live mice after infusion of fluorescent tracers, showed
that during sleep there was a 60% increase in the interstitial
space, allowing an increase in exchange between cerebrospinal
fluid (CSF) and interstitial fluid. This has important implications
for the clearance of interstitial disease-associated proteins (Xie
et al., 2013) and highlights a role for sleep in maintaining
brain homeostasis.
TBI – INFLAMMATION AND SLEEP
PATHOLOGY
Mechanical forces applied to the head or brain initiate TBI,
wherein sequential pathophysiological processes permanently
change neurological function (Masel and DeWitt, 2010; Corrigan
and Hammond, 2013). TBI survivors suffer irreversible cognitive,
sensory, sleep, mental health, and emotional morbidities
as a consequence of injury-induced pathological processes
(McAllister, 1992; Kempf et al., 2010). TBI can cause neuronal cell
death, ischemia, hemorrhage, and the disruption of the blood-
brain barrier (BBB) which elicit neuroinflammatory cascades
(Pleines et al., 2001). Such secondary injury can exacerbate
the damage caused by the initial impact if left unresolved.
Although the primary brain injury from TBI is irreversible, the
subsequent injury processes occur in a delayed fashion and may
be responsive to treatment.
Ongoing cellular events post-TBI often cause further damage
and lead to physiological consequences (Werner and Engelhard,
2007; Prins et al., 2013). Among these, sleep disturbances after
TBI are commonly reported in the acute timeframe post-injury by
up to 70% of TBI survivors (Cohen et al., 1992; Orff et al., 2009).
Sleep disturbances may persist chronically (Castriotta et al., 2007;
Verma et al., 2007; Kempf et al., 2010), and are experienced
across the spectrum of TBI patients, including children and
adolescents (Tham et al., 2012). These sleep disturbances in TBI
survivors ultimately impact their quality of life. Identification
and treatment of sleep-wake disturbances following TBI can
improve outcomes in vigilance, working memory, and capacity
of language processing (Wiseman-Hakes et al., 2013). Excessive
daytime sleepiness is the most common sleep-wake disturbance
reported among TBI patients (Castriotta et al., 2007; Kempf
et al., 2010; Baumann, 2012) and is characterized primarily by an
increase in sleep propensity. Other commonly reported disorders
include post-traumatic hypersomnia, narcolepsy, delayed sleep
phase, insomnia, and fatigue (Ouellet and Morin, 2006; Verma
et al., 2007; Kempf et al., 2010; Baumann, 2012; Billiard and
Podesta, 2013). These sleep disturbances negatively impact
rehabilitation of TBI patients and can exacerbate symptoms
such as pain and cognitive deficits (Mathias and Alvaro, 2012;
Bhalerao et al., 2013).
Extensive pre-clinical research has focused on the detrimental
effects of inflammation on the injured brain. In rodent models
of TBI, microglia respond immediately to brain injury-induced
tissue damage and release inflammatory mediators such as
inflammatory cytokines and chemokines that have been shown
to alter sleep (Morganti-Kossmann et al., 2001; Davalos et al.,
2005; Nimmerjahn et al., 2005; Frugier et al., 2010; Semple
et al., 2010; Ziebell and Morganti-Kossmann, 2010; Bachstetter
et al., 2013). Two-photon microscopy images of fluorescently
labeled microglia following a laser-induced injury demonstrated
rapid proliferation and migration of microglia to the site of
injury, where their processes fused (Davalos et al., 2005). It
was hypothesized that this fusion event was to create a barrier
between healthy and injured tissue (Davalos et al., 2005). These
findings suggest that microglia may be the first line of defense
following TBI (Kumar and Loane, 2012). However, microglia can
become over-activated and induce detrimental neurotoxic effects
through the overproduction of cytotoxins, including cytokines
(Block and Hong, 2005). Uncontrolled cytokine production
by activated microglia can significantly influence activation of
astrocytes, which can increase neuronal cell death and worsen
outcomes after TBI (Myer et al., 2006). Together, these results
support the view that the inflammatory response to TBI possesses
both beneficial and detrimental effects that likely differ in the
acute and delayed phase after injury.
In the mouse, diffuse brain injury has been shown to increase
the parameters of sleep for 6 h post-injury, regardless of
sex, injury severity, or time of day the injury occurs (Rowe
et al., 2014b; Saber et al., 2019). This period of post-traumatic
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sleep correlates with elevated central and peripheral cytokine
levels, particularly SRSs. Subsequent studies have shown sleep
impairment at light-dark transitions, suggesting possible TBI-
induced disruption of circadian rhythms (Lim et al., 2013;
Rowe et al., 2014a). Whether post-traumatic sleep is beneficial
or detrimental to neurological outcome from TBI remains
unresolved. To advance the understanding of post-traumatic
sleep, a gentle handling approach was used to keep both
uninjured and brain-injured mice awake over the 6 h of post-
traumatic sleep. In this study, a single period of sleep deprivation
demonstrated no adverse, long-standing neurological effects
(Rowe et al., 2014a), although, the course of recovery from
injury may have been altered. Three days of transient sleep
disruption following experimental TBI in the mouse worsened
inflammation and altered stress-immune pathways (Tapp et al.,
2020). Total sleep deprivation for 24 h following diffuse TBI
in rats reduced morphological damage and improved functional
outcome in the acute recovery period (Martinez-Vargas et al.,
2012). The effect of sleep deprivation prior to TBI has also
been investigated and 48 h of sleep deprivation or chronic sleep
restriction (10 days, 6-h sleep/day) prior to mild or moderate
TBI in rats did not exacerbate brain injury-induced neuronal
damage (Caron and Stephenson, 2015). Sleep after TBI has also
been inhibited pharmacologically. The therapeutic treatment of
mice with an anti-inflammatory lipid mediator, and treatment
with a novel TNF-α inhibitor, attenuated TBI-induced sleep and
subsequently improved functional outcome (Harrison et al., 2015;
Rowe et al., 2018b). When a second TBI was introduced during
post-traumatic sleep (3 h apart), more severe functional and
histopathological outcomes were observed, when compared with
mice that received a second TBI after sleep from the initial impact
subsided (Rowe et al., 2018a). Taken together, these studies
suggest that more evidence is needed to determine if acute sleep
after TBI is beneficial or detrimental, however, the underlying
pathological response to brain injury that results in increased
sleep may be amenable to therapies. Furthermore, post-traumatic
sleep may be a physiological response to brain injury that could
serve as a personalized biomarker to pathological conditions. In
moderate to severe clinical cases of TBI, sleep-wake cycles can be
altered due to a loss of consciousness. Clinical data indicate when
the brain has not recovered consciousness from a moderate to
severe TBI, it is not able to consolidate sleep or generate a 24-h
sleep-wake cycle (Duclos et al., 2017). These clinical data parallel
experimental data and suggest in the acute phase of TBI, injury-
induced pathophysiology contributes to sleep disturbances.
Although inflammation has emerged as a major player in sleep
disturbances post-TBI, there are other influences that should be
considered. TBI can cause widespread mechanical damage to
regions of the brain, many of which exert a role in sleep and
inflammation. One region of particular interest to understanding
sleep disturbances post-TBI is the hypothalamus (Sundaram
et al., 2013). Damage or loss of hypothalamic neurons can disrupt
orexin (a.k.a. hypocretin) secretion which has a well-established
role in arousal and wakefulness. Extensive loss of orexin neurons
and consequent excessive daytime sleepiness have been observed
both pre-clinically and clinically after TBI (Baumann et al., 2009;
Thomasy et al., 2017; Thomasy and Opp, 2019). Experimental
TBI in the mouse decreased wake and increased non-rapid eye
movement (NREM) sleep during the dark period and reduced
orexin cells as a function of injury severity up to 2 weeks post-
injury (Thomasy et al., 2017). Orexin (hypocretin) knockout
mice subjected to TBI did not exhibit altered sleep, whereas
control wild type mice had increased NREM sleep and decreased
wake up to 1 month post-TBI (Thomasy and Opp, 2019). A
prospective clinical study found that TBI survivors who reported
excessive daytime sleepiness had reduced CSF orexin levels up to
6 months post-injury (Baumann et al., 2007). Together, these data
support that the orexinergic system may be involved in long-term
sleep-wake alterations that persist after the acute inflammatory
response to TBI has subsided. Therefore, orexins should be
considered when discussing the sleep-mediated links between
TBI and AD (Liguori, 2017). However, the complexity of this
relationship must be noted as not only has increased orexinergic
signaling been associated with the progression of AD, orexins
have been shown to increase amyloid-β in the interstitial fluid
(Kang et al., 2009) and there is a documented correlation between
tau proteins and orexin CSF levels and sleep-wake dysregulation
in AD patients (Liguori et al., 2020b). Furthermore, damage to
the hypothalamus and pituitary can affect the endocrine system in
general (Sundaram et al., 2013), with potential for further impact
on sleep architecture that is currently poorly understood.
DYSREGULATED IMMUNE FUNCTION
AND SLEEP
The immune system is the body’s defense system which
monitors, detects, and attempts to eliminate threats to health and
homeostasis. Immune cells communicate via chemical mediators
such as cytokines and chemokines allowing them to respond
to pathological changes within tissues with a high degree of
specificity. While the peripheral immune system plays a role
in the disease progression of TBI and AD, the inflammatory
reactions observed in these conditions are largely driven by
microglia, the immune cells exclusive to the CNS. There are
bidirectional links between sleep and the immune system, such
that sleep loss impairs immune function and physiological
sleep is modified in response to an immune challenge (Ingiosi
and Opp, 2016). Sleep/circadian disturbances, particularly states
of sleep disruption and deprivation, can lead to serious
consequences; for example, dysregulation of the inflammatory
response (Castanon-Cervantes et al., 2010; Besedovsky et al.,
2019), leading to a state of systemic inflammation with increased
pro-inflammatory cytokines in the brain (Marshall and Born,
2002; Opp and Toth, 2003; Maurovich-Horvat et al., 2008;
Aldabal and Bahammam, 2011).
Cytokines and Sleep
Cytokines have an essential role in regulating the immune
system at multiple stages throughout the body and have
long been characterized as a contributing factor to sleep and
sleep disturbances. Under normal conditions, cytokines have
been shown to play a role in NREM sleep (Shoham et al.,
1987; Morrow and Opp, 2005; Krueger, 2008), as well as
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altering neuronal firing patterns in both the hypothalamus and
brainstem, with consequent effects on sleep regulation (Opp,
2005). Interleukin (IL)-6, tumor necrosis factor (TNF)-α, and
IL-1β, are well characterized for their essential role in both
sleep and inflammation and mediate the crosstalk between the
peripheral immune system and the brain (Krueger and Majde,
1995; Krueger, 2008; Besedovsky et al., 2019). Mechanistically,
this property of IL-6, TNF-α, and IL-1β, could be linked to their
neuromodulatory effect in contributing to the fine-tuned control
of synaptic transmission and plasticity (Jewett and Krueger,
2012; Vezzani and Viviani, 2015), which contributes to the
function of memory formation during intermittent rapid eye
movement (REM) sleep and NREM sleep (Walker, 2017). As
such, increased production of these pro-inflammatory cytokines
mediates increases in sleep under inflammatory conditions
such as TBI or AD.
There is also a relationship between sleep disturbances and
cytokine production [Please see (Irwin, 2019) for an excellent
review on sleep and cytokines]. The sleep disturbances that
occur in neurological disease and injury (Musiek and Holtzman,
2016; Leng et al., 2019; Logan and McClung, 2019) are likely
due to common pathological pathways that activate the immune
response; specifically, inflammation and cytokine production.
Prolonged wakefulness increased cytokines in the CSF (Borbely
and Tobler, 1989; Krueger et al., 2001), which can lead
to subsequent sleep disturbances. In one study, REM sleep
deprivation for 72 h in rats led to significant increases in plasma
IL-6, IL-1β, and TNF-α expression, but the expression of IL-6
and IL-1β returned to levels of controls 1-week after the period
of sleep deprivation ended, while TNF-α remained elevated
(Yehuda et al., 2009). Moreover, sleep deprivation increased IL-
1β and TNF-α mRNA expression in cortical and subcortical
brain regions in rats (Zielinski et al., 2014). Similarly, in humans
with experimental chronic circadian sleep disruption, there was
a significant increase in plasma TNF-α expression (Wright
et al., 2015). A meta-analysis also showed that in humans,
sleep disturbances increased plasma IL-6, although no significant
changes were found in TNF-α expression, likely owing to the
low statistical power in the analysis (Irwin et al., 2016). These
studies support a bidirectional relationship between these pro-
inflammatory cytokines and sleep. Increases in these cytokines
lead to increased sleep, and conversely, sleep deprivation and
disruption can increase these cytokines. However, a recent study
showed that TNF-α knockout mice display similar patterns of
sleep and no deficiency in sleep regulation compared with wild
type mice (Szentirmai and Kapás, 2019). In fruit flies, knockdown
of the TNF-α homologue in astrocytes, but not neurons, reduced
sleep duration and disrupted sleep-rebound following sleep
deprivation (Vanderheyden et al., 2018). As such, although IL-
6, IL-1β, and TNF-α promote sleep, these cytokines may have a
larger role in regulating sleep following inflammatory insults such
as after TBI or during the chronic inflammatory events of AD.
Moreover, cytokines have functional implications in both TBI
and AD. Following a TBI, there is a profound increase in the
production and release of cytokines (Figure 1). Acutely, the
increased release of cytokines is believed to have therapeutic
implications that can help improve primary and secondary
injury (Gyoneva and Ransohoff, 2015; Plesnila, 2016). However,
chronically elevated cytokine levels can further perpetuate the
initial damage and lead to robust secondary damage (Morganti-
Kossman et al., 1997; Zeiler et al., 2017). Similarly, in AD, a
dysregulation of cytokines may potentiate the pathogenesis of the
disease leading to irreversible damage (Su et al., 2016; Figure 1).
Indeed, plasma cytokines are higher in the AD population when
compared with healthy controls (Swardfager et al., 2010). In the
context of this review, we assert that sleep disturbances, brought
about by either TBI or AD, lead to changes in cytokine production
and may further exacerbate disease-related damage to the brain.
ALZHEIMER’S DISEASE –
INFLAMMATION AND SLEEP
PATHOLOGY
Sleep disturbances have long been a symptom associated with AD
but more recently have been recognized as an early feature of the
disease, thought to precede cognitive decline and contribute to
disease progression (Musiek et al., 2015; Musiek and Holtzman,
2016). Literature reports that 25–70% of all suspected AD patients
report disturbances in sleep which are linked to poorer disease
prognosis (Moran et al., 2005; Craig et al., 2006; Beaulieu-
Bonneau and Hudon, 2009; Lim et al., 2014; Wennberg et al.,
2017). A recent study found that 20% of people between 25 and
45 were sleeping 90 min less than the recommended amount for
their age group (Léger et al., 2011). This raises the question as
to whether irregular sleep in early life contributes to developing
AD later in life.
Sleep is important for clearing pathological and inflammatory-
associated proteins from the brain. The recently discovered
glymphatic system clears unwanted or pathological proteins from
the interstitial space in the brain by exchange between the
CSF the interstitial fluid (ISF) (Xie et al., 2013). Aquaporin-4
water channels, located on the end feet on astrocytes, mediate
the process by allowing ISF flow from the interstitial space
into the paravenous region, which in turn drains through the
lymphatic system (Verheggen et al., 2018). This is the process
by which solutes are removed from the brain. Further, it has
been shown that the level of amyloid-β in the brain fluctuates
rapidly with the daily sleep-wake cycle. During sleep, there is
a 60% increase in the flow of ISF to CSF. Therefore, it is
postulated that the disturbed sleep of AD patients decreases
the exchange of ISF and CSF which may lead to reduced
clearance of soluble amyloid-β, contributing to the formation
of plaques (Xie et al., 2013; Rasmussen et al., 2018). In
turn, increased amyloid burden can lead to an upregulated
level of inflammation, perpetuating the cycle. Clinically, this
effect has been observed using accelerated neuroimaging;
blood oxygen level, functional magnetic resonance imaging,
electroencephalogram, and CSF flow. Using these techniques,
waves of CSF flow were observed during slow wave sleep,
which appeared to be coupled with the hemodynamic rhythm
during sleep (Fultz et al., 2019). Further, a recent clinical
study that examined the sleep architecture and CSF biomarkers
(tau and amyloid-β42) in patients with AD (which progressed
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from having subjective cognitive impairment to mild cognitive
impairment to AD), found that both REM and NREM sleep
were disturbed. They also found that AD patients displayed
a decrease of CSF amyloid-β42 (Liguori et al., 2020a). In the
clinic, amyloid-β deposition has been shown to accumulate
prior to cognitive and memory decline (Liguori et al.,
2020a) and this effect was significantly higher in those who
also had poor sleep efficiency (Molano et al., 2017). Other
experimental studies on human volunteers have also suggested
that dysregulated sleep patterns increase amyloid-β deposition
in the human brain (Shokri-Kojori et al., 2018). Together,
these data demonstrate how the self-perpetuating cycle of sleep
disturbance and inflammation are associated with a decline in
cognitive function.
Pre-clinically, transgenic mice overexpressing disease-
associated APPswe/PS1δE9 mutations which drive amyloid-β
pathology, exhibit disturbed sleep patterns prior to developing
amyloid-β plaques (Roh et al., 2012). This disturbance further
emphasizes the potential bidirectional relationship between
amyloid-β deposition and sleep regulation. However, whether
the detrimental cycle is between sleep and amyloid-β directly,
or rather associated inflammatory factors (or a combination
of both) is unknown. The extent to which amyloid-β acts
as a driver of AD progression remains controversial, but it
does appear very likely that inflammation increases amyloid-β
deposition (Irwin and Vitiello, 2019). Clinically, the AD brain
presents with activated microglial phenotypes, most notably
aggregated in the penumbra of amyloid-β plaques (Navarro
et al., 2018) (see Figure 2; further discussed in section “TBI as
a Contributor to AD”), where their likely/presumed function
is to reduce neuronal exposure to soluble amyloid β-mediated
toxicity (Wang et al., 2016). In the post-mortem AD brain,
other morphological changes in microglia are seen, such as
rod and dystrophic phenotypes, as well as an overall increase
in microglial density (Figure 2; Bachstetter et al., 2015). This
suggests that the role of microglia in AD is probably more
complex than simply clearing amyloid-β and associated proteins
(as represented in Figure 2). Despite the elusiveness of their
function, these altered microglial phenotypes are associated with
an increased release of pro-inflammatory cytokines known to
cause sleep disturbances and neuronal toxicity (Lull and Block,
2010), thus, through this mechanism microglia can contribute
to the progression of AD. In summary, both pre-clinical
and clinical research suggests a complex interaction between
sleep and the microglia-mediated inflammatory response
in the AD brain.
Both sleep and inflammation are tightly coupled to the
cholinergic system, which promotes wakefulness and REM
sleep (Platt and Riedel, 2011). Irreversible damage to the
basal forebrain cholinergic system correlates with the memory
and cognitive symptoms seen in AD (Ferreira-Vieira et al.,
2016). Moreover, the immune response is in part regulated
by the cholinergic anti-inflammatory pathway by control of
macrophages and microglia through α7 nicotinic receptors. Such
modulation attenuates the release of pro-inflammatory cytokines,
namely TNF-α, as shown in vitro and in vivo (Shytle et al.,
2004; Lehner et al., 2019) and might be compromised by the loss
FIGURE 2 | Depiction of a coronal brain slice showing the global expanse of
microglial phenotypes in TBI and AD. The left illustrates localized effects of TBI
which include increased microglial activation near the injury site and
decreased activation in distal regions. In comparison, the right represents the
AD brain with widespread changes in microglia morphology, gross structural
changes to the cortex, and an enlargement of ventricles (gray). Both TBI and
AD lead to increased inflammation and activated microglia. Despite this
similarity, distinct microglial morphologies are observed in these conditions. (1)
Microglia are activated, migrate to the injury site, and display an amoeboid or
phagocytic morphology. (2) Rod-cell morphology is often observed in the
cortex after TBI and have also been documented in AD tissue. However, the
function of this cell phenotype is currently unknown, and the morphology is
not restricted to TBI/AD or the region in which they are shown. (3) Distal to the
injury site, microglia are ramified and occur at a lower density. (4) Microglia
that surround amyloid-β plaques show activated, amoeboid, and dystrophic
morphologies. Cells of each phenotype pictured are not restricted to the brain
regions shown.
of acetylcholine from basal forebrain neurons in AD. Although
the acetylcholinesterase inhibitors donepezil, galantamine, and
rivastigmine (drugs currently licensed to treat the symptoms
of AD) would be anticipated to boost acetylcholine levels,
they have a poorly defined effect on sleep architecture (Cooke
et al., 2006). One study found an 81.8% improvement in sleep
quality with galantamine treatment, 75% with rivastigmine,
and 50% from donepezil (Naharci et al., 2015). Despite these
reported improvements, the treatment of sleep disturbances
in AD patients remains a clinical challenge. Glutamatergic
signaling, which plays an integrated role in the regulation of
sleep stages and arousal (Shi and Yu, 2013), also deteriorates
in AD patients. Memantine, a moderate affinity N-methyl-D-
aspartate receptor antagonist, has been shown to increase total
time spent sleeping in AD patients treated with 20 mg/day for
4 weeks (Ishikawa et al., 2016). However, due to the nature
of receptor desensitization and transient efficacy of this drug,
it is not a good long-term pharmacological candidate to break
the altered sleep architecture and inflammation cycle discussed
here. In the search for a more effective intervention, multiple
neuroinflammatory molecules have been targeted as potential
treatments for AD but have had limited success in measurable
outcomes. Currently, there is renewed interest in microglia
as a therapeutic target to stop the pathological inflammatory
cascades seen in AD which could then potentially treat sleep
Frontiers in Neuroscience | www.frontiersin.org 6 August 2020 | Volume 14 | Article 894
fnins-14-00894 August 24, 2020 Time: 17:29 # 7
Green et al. Sleep, Inflammation, Neurodegeneration
disturbances, as discussed in section “TBI to AD – A Microglial
Mediated Progression?”.
TBI as a Contributor to AD
Meta-analyses have found that a history of TBI is associated
with development of AD (Mortimer et al., 1991; Fleminger et al.,
2003). Despite different mechanisms of onset, these conditions
are mechanistically interlinked by a complex web of pathologies,
as demonstrated by Figure 1. Furthermore, increased amyloid-
β levels are seen after TBI (Sivanandam and Thakur, 1995;
Rasmusson et al., 1995; Nemetz et al., 1999; Jellinger et al., 2001)
and post-mortem examination of TBI brains found that amyloid-
β plaques, a hallmark of AD, had developed acutely in 30% of
TBI brains (Roberts et al., 1991; Roberts et al., 1994; Johnson
et al., 2010). However, as amyloid-β plaques are also seen in
the healthy brain (Rodrigue et al., 2009), the meaning of these
findings are unclear. While there is an increased risk of AD after
TBI, most individuals with AD do not have a history with TBI,
thus, other factors may interact with TBI-induced damage and
lead to exacerbated cognitive decline and dementia (Plassman
and Grafman, 2015). As discussed above, sleep disturbances post-
TBI correlate with microglial activation and a concomitant rise in
pro-inflammatory cytokine levels (Rowe et al., 2014b). As sleep
disturbances have been identified as an early symptom of AD, it
is plausible that TBI-induced sleep disturbances are a risk factor
for AD. Until this is understood, the opportunity for therapeutic
intervention in this inter-disease period is stunted.
Breach of the Blood Brain Barrier –
Unregulated Infiltration of Plasma
Proteins
TBI, despite the varying causal mechanisms, initiates breach of
the BBB. Whether it be a transient opening due to the shearing
of blood vessels, or a chronic inflammation-mediated opening,
cross-talk between the CNS and the blood can occur. This is due
to disruption of the tight junctions that prevent uncontrolled
infiltration of substances from the blood, as summarized by
Figure 1. A scanning electron microscopy (SEM) study of the
human brain after death from TBI showed altered vascular
features (Rodríguez-Baeza et al., 2003). Microvascular casts
examined by SEM showed a sunken vascular surface, longitudinal
creases, and flattened luminal morphology (Rodríguez-Baeza
et al., 2003). A similar breach in neurovascular membranes has
been observed in many pre-clinical studies (Tanno et al., 1992;
Baldwin et al., 1996; Sangiorgi et al., 2013). Not only does the
initial brain injury cause BBB breach from the sheering caused
by the mechanical force exerted on the brain, but secondary
processes such as inflammation and hypoxia contribute to
prolonged breach of the BBB creating a self-perpetuating,
unregulated cycle of cross-talk between the CNS and the blood.
Alongside TBI, BBB breach is a well-known consequence of many
other inflammation-inducing conditions such as viral or bacterial
infection. Amyloid-β has also been shown to cause cerebral-
amyloid angiopathy (the presence of amyloid-β aggregates in the
vasculature of the brain) which adds to the perpetual, unregulated
infiltration of blood components into the brain as this also
causes further loss of blood vessel integrity leading to brain
hemorrhage (Smith and Greenberg, 2009). As both mechanical
damage and infiltration of pro-inflammatory molecules that
travel in the blood increase the inflammatory microenvironment
after TBI, this may increase the likelihood of developing AD, and
its consequent sleep disturbances, that are known to be tightly
associated with inflammation.
Matrix metalloproteases (MMPs) are key enzymes that cause
breakdown of BBB integrity, and therefore the infiltration of
products into the brain (Nissinen and Kähäri, 2014). MMP9
knockout mice have shown the deleterious role of MMPs in
maintaining a chronic ischemic environment after a transient,
focal ischemic injury (Asahi et al., 2001), as the absence of
MMP9 reduced proteolytic breakdown of the BBB. Further,
MMPs increase the bioavailability of both TNF-α (Haro et al.,
2000; Vandenbroucke et al., 2013) and IL-1β (Schönbeck et al.,
1998; Nissinen and Kähäri, 2014), two major inflammatory
cytokines that can cause breach of the BBB independent of injury
(Siegel et al., 2009). Not only does this lead to a chronic pro-
inflammatory environment of the brain, but TNF-α and IL-1β
act as SRSs, the increase of which can cause sleep disturbances.
The disruption of sleep patterns feeds into the upregulation of
inflammation and is a key feature of AD which can precede
cognitive decline. When considered together, this body of
literature suggests that MMPs are mediators of the perpetual
pathological feedback loop initiated by TBI and postulated to
increase the risk of developing AD.
Amyloid-β and Tau as Mediators of
Inflammation and Sleep Disturbance
It is well established that TBI can cause disruption to
the BBB, henceforth, crosstalk between the CNS and
peripheral organ systems is initiated. Not only can this allow
infiltration of peripheral cytokines (which further exacerbate
neuroinflammation), but soluble forms of amyloid-β and tau
can move across the BBB. The following section will discuss
the role of these proteins in the inflammatory mediated sleep
disturbances seen during the progression of both TBI and AD.
There is little known about the brain-wide concentration of
oligomeric and unaggregated forms of amyloid-β, a protein that
is found in high abundance peripherally with respect to the
brain. As TBI creates an opportunity for amyloid-β proteins
to cross the BBB, the clinical and biochemical impact of this
is under much dispute. One study examined patients with a
severe TBI and found that amyloid-β peptides (amyloid-β 1–42
and 1–40) were increased in the CSF, peaking 1 week post-
injury (Raby et al., 1998). Increased levels of tau and amyloid-
β were also observed in blood exosomes (Gill et al., 2018).
Such increases in these proteins may be reflected in increased
levels in CSF, however, evidence has proven inconsistent. For
example, two studies reported that amyloid-β in the CSF was
significantly lower than in controls during the week following
TBI (Franz et al., 2003; Kay et al., 2003). Despite the disparity
of these findings, it could be interpreted that CSF amyloid-β
decreased post-injury due to possible deposition in the brain.
However, as sleep disturbance post-TBI peaks in the acute
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time phase, and sleep disturbance increases soluble amyloid-
β in the CSF (Lucey et al., 2018), the findings of these
studies are conflicting. Moreover, researchers have shown that
the anti-inflammatory antibiotic doxycycline can attenuate the
acute behavioral deficits associated with intracerebral delivery
of oligomeric amyloid-β (Forloni and Balducci, 2018), which
acts as proof of principle; unaggregated forms of amyloid-β and
inflammation are tightly coupled.
Not only does infiltration of amyloid-β and tau directly affect
the formation of plaques and tangles and increase oligomeric
toxic species, but infiltration of associated proteins can also have
an effect. For example, S100A9 (a pro-inflammatory protein) has
been shown to contribute to amyloid plaques that accumulate
rapidly after TBI. These plaques were found to be positive for
oligomeric forms of amyloid-β and not fibrillar forms, suggesting
that these could be a precursor to the plaques seen in later
stage AD (Wang et al., 2014). Further, it has been well accepted
that the levels of iron, copper and zinc are altered in the
brain of AD patients and that amyloid-β plaques are sites of
metal aggregation. Experimental models of TBI have also shown
that there is increased infiltration of metal ions (iron, copper
and zinc) post-TBI. Under normal physiological conditions,
such ions are found in the blood and are prevented from
freely moving across the BBB. Amyloid-β has been shown to
associate with zinc, copper and iron ions (Lovell et al., 1998),
which are all present in the blood, therefore, the increased
level of blood in the brain after TBI is likely to exacerbate
this association. This increase in ion concentration is therefore
likely to augment plaque formation, increasing plaque-associated
inflammation. Another well characterized contributor to AD is
oxidative stress caused by the rapid production of free radicals. As
sleep fosters antioxidant activity, sleep disruption may exacerbate
ROS activity and associated inflammation post-TBI, which can
lead to neuronal cell death and further aggregation of amyloid-β
(Molina-Holgado et al., 2007).
TBI can also augment the formation of amyloid-β plaques
and tau neurofibrillary tangles (NFTs) through inflammation-
dependent gene expression and transcription factor activation.
Experimental TBI in the 3xTg mouse model of AD, showed
that TBI activated transcription factors (CCAAT/Enhancer
Binding Protein Beta), and increased the expression of delta-
secretase (Wu et al., 2019). Delta-secretase is an enzyme that
mediates pathology by cleaving amyloid-β and tau which allows
the formation of amyloid-β plaques and hyperphosphorylated
tau, and consequently induces the neuroinflammatory cascade
(Zhang et al., 2020). Support for the hypothesis that TBI
augments the formation of amyloid-β plaques and NFTs
was strengthened by the fact that the authors reversed the
effect using viral expression of tau in 3xTg mice, that was
resistant to cleavage by delta secretase (Wu et al., 2019).
These data demonstrate how amyloid- β and tau contribute
to the inflammatory microenvironment (and consequent sleep
disturbances) associated with both TBI and AD.
NFTs are another hallmark of AD. In both mice and humans,
NFTs have been found post-TBI (Kondo et al., 2015) and play
a critical role in post-injury neuronal damage (Smith et al.,
1999; Duda et al., 2000; Uryu et al., 2007; Yao et al., 2008;
Johnson et al., 2012). NFTs impair axonal transport, notably
of mitochondria (which are necessary for supporting nerve
terminal function), contributing to the neuronal death associated
with TBI (Kondo et al., 2015). Tau acts intracellularly as a
microtubule stabilizer; however, its accumulation can occur
both intracellularly and extracellularly (Swanson et al., 2017).
Intracellularly tau abnormalities may cause neuronal death
through disruption of intracellular cargo transport, whereas
extracellular oligomers of tau are released from degenerating
neurons. This was shown by in-vitro studies, revealing addition
of un-aggregated tau protein increased the amount of cell
death in tau-treated cells compared to controls (Gómez-Ramos
et al., 2006). This suggests that extracellular tau is able to
transmit the pathology to neighboring neurons, which causes
spread of neuronal death from tauopathy (Swanson et al.,
2017). Further, tau induces synaptic loss through microglial
phagocytosis of synaptic compartments containing tau, leading
to synaptic loss and cognitive decline (Jadhav et al., 2015).
Alongside mediating the spatiotemporal spread of pathology, tau
can prolong microglial activation, exacerbating a chronic pro-
inflammatory environment in the brain, as shown in Figure 2.
A recent study using positron emission tomography has
identified an increased level of tau deposition in patients that
had suffered a single, moderate-severe TBI compared to controls
(Gorgoraptis et al., 2019). Pre-clinical rodent models have also
found an increase in oligomeric tau in the brain acutely (4 h) after
parasagittal fluid percussion injury, which remained elevated for
2 weeks post-injury compared to uninjured shams (Hawkins
et al., 2013). These studies support an increase in tau protein in
the brain after TBI and provides another link for an inter-disease
progression to AD triggered by TBI-induced BBB disruption.
Not only has tau been shown to have inflammatory
consequences, but a recent human study, using regression
analysis on positron emission tomography measures of amyloid-
β and tau, and EEG sleep recording, showed that the extent
of slow wave sleep disturbance predicted a greater presence of
tau in the medial temporal lobe (Winer et al., 2019). Numerous
studies using animal models also associate aggregates of tau with
disturbance to sleep or circadian regulation (Musalek et al., 1989;
Witton et al., 2016; Holth et al., 2017; Arnes et al., 2019). Taken
together the data presented in this section suggest a plausible
inter-condition link between TBI, AD through the inflammatory
and sleep mediated pathological cycle.
TBI TO AD – A MICROGLIAL MEDIATED
PROGRESSION?
Microglia, the immune cells exclusive to the CNS (Loane and
Byrnes, 2010), play a role in perpetuating homeostasis in the
CNS (Inoue, 2002), where they act as a biological surveillance
system continuously monitoring the microenvironment. This
allows them to be the first responders upon detection of
pathological stimuli (Glenn et al., 1992). Microglial activation
displays a morphological (and genetic) continuum, with changes
in characteristics enabling the cells to rapidly respond to stimuli.
Under normal conditions, microglia have a small cell soma
Frontiers in Neuroscience | www.frontiersin.org 8 August 2020 | Volume 14 | Article 894
fnins-14-00894 August 24, 2020 Time: 17:29 # 9
Green et al. Sleep, Inflammation, Neurodegeneration
and highly branched processes. After detection of pathological
stimuli, or sleep disturbance, the cell soma enlarges, and the
processes retract. This activated phenotype permits phagocytic
activity (Liu and Quan, 2018). Upon activation, microglia release
cytokines to trigger pro-inflammatory pathways. Despite some
immediate benefit seen from microglial activation, such as
clearing of cellular debris, their reactivity has been associated
with potentially damaging intermediates. These include reactive
oxygen species and pro-inflammatory cytokines (Norden and
Godbout, 2013; Iizumi et al., 2016), which can cause damage
to nearby neurons, prolong the inflammatory response, hinder
CNS repair, and exacerbate neurological symptoms, such as
inflammation-induced sleep (Dheen et al., 2007; Ziebell and
Morganti-Kossmann, 2010; Bilbo and Stevens, 2017). Further,
chronic microglial activation increases astrocyte activation,
which can worsen the outcome after an inflammatory challenge,
increasing neuronal cell death (Myer et al., 2006).
In response to pathological stimuli, microglia upregulate
their release of certain cytokines, including TNF-α, IL-1β, and
IL-6 which act as SRSs (see section “Cytokines and Sleep”).
A further consideration is that higher levels of microglial
activation are observed during waking hours; microglia return
to their non-activated status during sleep (Fonken et al., 2015).
As microglia upregulate their release of IL-1β and TNF-α upon
activation, it is likely that these cytokines fluctuate in response
to endogenous circadian regulation, though this is beyond the
scope of current experimental literature. If microglia return to
non-activated states during sleep, one would predict sleep is
neuroprotective following pathological stimuli, however, these
data are inconclusive and require further research (see section
“Alzheimer’s Disease – Inflammation and Sleep Pathology”).
The inflammatory cascade present in both AD and TBI
presents as an attractive target for therapeutic intervention.
Historically, cyclooxygenase, a key enzyme in prostaglandin
production, was identified as a target for reducing the
inflammatory response seen in AD, however, its inhibition with
nonsteroidal anti-inflammatory drugs (Aisen, 2002) had limited
efficacy in stalling the progression of AD. Due to observed
clustering of microglia around amyloid-β plaques, microglia have
emerged as a therapeutic target. Despite the growing volume of
multidisciplinary research on the activation of microglia and pro-
inflammatory cytokines as SRSs, the nuances of their involvement
in sleep are not yet fully understood. As dysregulation of
sleep has been associated with neurological deficits, a complex,
multifaceted feedback loop is created. This poses a difficult target
for therapeutic intervention, until the role of microglia in sleep
is fully unveiled.
Multiple areas of neuroscientific research have presented
cogent evidence suggesting that microglia can become “primed”
and display an activated phenotype chronically (Fenn et al.,
2014; Witcher et al., 2015; Hoeijmakers et al., 2016; Ziebell
et al., 2017). Microglia in the aged brain express “primed”
morphology, even under healthy conditions, a facet not observed
in the younger adult brain (Norden and Godbout, 2013; Loane
et al., 2014). Hypotheses suggest priming allows microglia to
respond more rapidly to injury and infection, however, the
link between chronic microglial priming and neurodegeneration
is under-explored (Norden and Godbout, 2013). Furthermore,
other cells of the glial network also show a more reactive
phenotype in the aging brain. Activation of astrocytes, with
their physical role in maintaining the integrity of the BBB,
may allow greater influx of soluble β-amyloid proteins into
the brain (see section “Amyloid-β and Tau as Mediators of
Inflammation and Sleep Disturbance”), thus advancing the
pathologies of the disease.
Much like in AD, a primed microglial phenotype has been
observed after TBI. One study in rodents showed that after TBI,
microglia remained sensitized and quickly became activated after
a peripheral immune challenge provided by lipopolysaccharide
(LPS). Mice that had received a TBI and LPS appeared to have
a poorer cognitive outcome, suggesting that microglial priming
worsens cognition (Muccigrosso et al., 2016). Another study
found that microglia displayed a primed morphology up to a
year after controlled cortical impact which appeared to augment
pathologies such as lesion volume, degeneration of hippocampal
neurons and myelin loss, which suggests microglial priming
may be, at least in part, a contributor to neurodegeneration
post-TBI (Loane et al., 2014). However, this relationship is
hard to pinpoint as not only do microglia express a primed
morphology with age and TBI, but also with other inflammatory-
associated conditions such as HIV (Hains et al., 2010), stroke
(Espinosa-Garcia et al., 2017), and even exposure to air pollution
(Mumaw et al., 2016).
After TBI, activated microglia have an increase in the
number of lysosomes (Tanaka et al., 2013). This has been
suggested to provide a link to the development of amyloid-
β plaques, because of the acidic lysosomal pH in comparison
with the extracellular microenvironment (Spangenberg et al.,
2019). This work was continued using histological staining
in human tissue and found an association between microglia
containing amyloid-β-aggregates which are hypothesized to lead
to progressive amyloid-β pathology (Spangenberg et al., 2019). To
further demonstrate the role of microglia in plaque formation,
elimination of microglia in a transgenic mouse model of AD
eliminated plaque formation, but plaques returned with the
recovery of microglia, which supports them having a role in
plaque formation.
Eliminating and repopulating microglia have shown
therapeutic efficacy in both AD and TBI. Eliminating microglia
using a bioavailable colony stimulating factor 1 receptor (CSF1R)
inhibitor, a receptor necessary for microglia survival, in a
5xFAD mouse model of AD showed amyloid-β plaques failed
to form in the absence of microglia but when the CSF1R
inhibitor was withdrawn, microglia repopulated and amyloid-β
plaques developed similar to those in controls (Spangenberg
et al., 2019). Similarly, the elimination of microglia with a
low dose of a bioavailable CSF1R inhibitor in 3xTg-AD mice
prevented microglia association with plaques and improved
cognitive function (Dagher et al., 2015). Another study showed
chronic microglia elimination did not alter amyloid-β loads
but prevented neuronal loss, rescued dendritic spine loss,
and improved cognitive behavior (Spangenberg et al., 2016).
Microglia elimination has been used in experimental TBI
studies where microglia elimination with a CSF1R inhibitor
prevented acute and chronic inflammatory responses in the
mouse and attenuated astrogliosis (Witcher et al., 2018). As a
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therapeutic intervention, chronically activated microglia were
eliminated using a CSF1R inhibitor 1 month following a focal
TBI, and the inhibitor was withdrawn 1 week later to allow
microglia to repopulate. These studies indicated that removal
of microglia after TBI reduced chronic neuroinflammation and
associated neurodegeneration and mice had improved functional
outcome (Henry et al., 2020). Taken together, these studies
support that microglia play a role the chronic inflammatory
response following TBI and contribute to AD pathology. If
eliminating microglia changes sleep profiles in the context of TBI
or AD has yet to be explored, however, these experiments may
offer further therapeutic approaches to mitigate inflammation-
mediated sleep disturbances.
CONCLUSION
This review documents the complexity of the multidirectional
relationship between sleep, microglia, and inflammation in the
clinical and pre-clinical contexts of TBI and AD. It is posited
that the inflammatory cascades triggered by the disturbed sleep
observed in TBI and AD creates the perfect storm, resulting
in a highly dynamic inter-disease trajectory. To this end, the
proposed sleep and inflammation-mediated link between TBI
and AD presents an opportunity for a multifaceted approach to
clinical intervention.
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